XIPERE Drug Patent Profile

Which patents cover Xipere, and when can generic versions of Xipere launch?

Xipere is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are four patents protecting this drug.

This drug has eighty-eight patent family members in nineteen countries.

The generic ingredient in XIPERE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-eight suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xipere

A generic version of XIPERE was approved as triamcinolone acetonide by SUN PHARMA CANADA on October 1^st, 1986.

Summary for XIPERE

International Patents:	88
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	83
Patent Applications:	4,516
Drug Prices:	Drug price information for XIPERE
What excipients (inactive ingredients) are in XIPERE?	XIPERE excipients list
DailyMed Link:	XIPERE at DailyMed

See drug prices for XIPERE

Pharmacology for XIPERE

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for XIPERE

XIPERE is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	XIPERE	triamcinolone acetonide	SUSPENSION;INJECTION	211950-001	Oct 22, 2021		RX	Yes	Yes			Y
Bausch And Lomb Inc	XIPERE	triamcinolone acetonide	SUSPENSION;INJECTION	211950-001	Oct 22, 2021		RX	Yes	Yes			Y
Bausch And Lomb Inc	XIPERE	triamcinolone acetonide	SUSPENSION;INJECTION	211950-001	Oct 22, 2021		RX	Yes	Yes
Bausch And Lomb Inc	XIPERE	triamcinolone acetonide	SUSPENSION;INJECTION	211950-001	Oct 22, 2021		RX	Yes	Yes

International Patents for XIPERE

See the table below for patents covering XIPERE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2017272182	Methods and devices for the treatment of ocular diseases in human subjects
Japan	6613342
Spain	2813869
Japan	2016520383	眼球注射の装置および方法

Market Dynamics and Financial Trajectory for XIPERE

Last updated: January 16, 2026

Executive Summary

XIPERE (hreluvatide ophthalmic suspension) is a novel corticosteroid approved by the FDA in December 2021 for the treatment of macular edema associated with non-infectious uveitis (NU). As the first intravitreal steroid authorized for this indication, its market positioning and revenue prospects are shaped by factors including regulatory status, macroeconomic trends, competitive landscape, and evolving ophthalmology treatment paradigms. This analysis evaluates the key drivers influencing XIPERE’s market dynamics and forecasts its financial trajectory over the next five years, juxtaposed against current market conditions, pipeline activity, and strategic opportunities.

---

What are the Market Fundamentals for XIPERE?

1. Therapeutic Market Size

• Prevalence of Uveitis: Affects approximately 17-52 per 100,000 population globally, with non-infectious uveitis comprising about 70-80% of cases.[1]
• Macular Edema in Uveitis: Occurs in roughly 70% of uveitis patients, representing a significant segment needing targeted therapy.
• Market Value: The global ophthalmic corticosteroids market was valued at USD 1.2 billion in 2021 and is projected to reach USD 1.8 billion by 2028, growing at a CAGR of 6-7%.[2]
• Impacted Population: Millions suffer from uveitis and associated macular edema, creating a substantial unmet need for effective, localized treatments.

2. Regulatory and Reimbursement Landscape

• FDA Approval: Instrumental in enabling initial market entry; future approvals in other jurisdictions (e.g., EMA) could expand geographic footprint.
• Reimbursement Policies: Coverage decisions by Medicare, Medicaid, and private insurers influence adoption rates. Corticosteroids typically benefit from favorable reimbursement due to established clinical efficacy.
• Pricing Dynamics: Limited competition serves as a potential leverage point for premium pricing; however, negotiations and biosimilar threats could pressure margins.

3. Competitive Environment

Competitors	Products/Licensing Status	Market Position
Ozurdex (Allergan)	Dexamethasone implant, FDA-approved for uveitis-related macular edema	Established, proven efficacy, longer market presence
Yutiq (EyePoint Pharmaceuticals)	Fluocinolone acetonide implant for uveitis	Sustained-release, less invasive option
Off-label corticosteroids	Various formulations and routes (IV, topical)	Widely used but lacks formal approval

• XIPERE's Unique Selling Point: First intravitreal hreluvatide suspension with specifically tailored pharmacokinetics for uveitic macular edema.

4. Market Penetration and Adoption Factors

• Medical Oncologists and Ophthalmologists' Acceptance: Influenced by clinical data, ease of administration, safety profiles.
• Dosage Frequency: XIPERE’s proposed dosing—initial injection followed by re-treatment—compared with existing therapies impacts patient adherence.
• Safety Profile: Lower corticosteroid-related side effects (e.g., intraocular pressure spikes, cataracts) can accelerate adoption.

---

How Will Market Dynamics Influence XIPERE’s Financial Performance?

1. Revenue Projections and Growth Drivers

Year	Expected Market Penetration	Estimated Revenue (USD millions)	Key Assumptions
2023	5% of diagnosed patients	$50 million	Launch momentum, initial penetration, moderate competition
2024	12%	$120 million	Increased adoption, payer coverage solidifies
2025	20%	$200 million	Competitive differentiation, expanded reimbursement
2026	25%	$250 million	Market acceptance, pipeline catalysts begin effect
2027	30%	$300 million	Dominance in niche market, healthcare policy shifts factor

Note: These estimates assume aggressive uptake driven by clinical convenience and superior safety profile.

2. Pricing Strategies

• Premium Pricing: Launched at approximately USD 3,500 per dose, aligned with market standards for intravitreal corticosteroid implants.
• Rebates and Negotiation: Expected to influence net pricing, especially as formulary inclusion expands.
• Insurance Coverage: Critical to achieving projected revenue; initial coverage likely favorable given indication and existing corticosteroid use.

3. Potential Challenges

• Competitive Launch Risks: Ozurdex’s entrenched positioning may slow initial uptake.
• Pricing Pressure: Future biosimilar entries or alternative therapies could lead to concessions.
• Regulatory Delays or Restrictions: Side effect profiles or manufacturing issues could impede growth.

---

What Are the Strategic Opportunities for Maximizing Financial Outcomes?

• Extension Indications: Exploring use in other forms of uveitis or ocular inflammatory diseases.
• Global Expansion: European Medicines Agency (EMA) approval anticipated; other markets (Japan, China) represent growth vectors.
• Combination Therapy Development: Partnering with biologics or immunomodulators to establish dual mechanisms.
• Enhanced Patient Engagement: Digital health technologies could improve adherence, expand market reach.

---

How Do Market Trends and Policy Changes Impact the Outlook?

Trend / Policy Item	Effect on XIPERE Market Trajectory	Status/Notes
Shift Toward Precision Medicine	Greater demand for targeted localized therapy	Favorable for intravitreal steroids
Reimbursement Tightening	Necessitates demonstrating cost-effectiveness	Requires robust payer negotiations
Emergence of Biosimilars	Potential price competition	Biosimilars for corticosteroids are emerging
COVID-19 Pandemic Influence	Delays elective procedures, impacting initial uptake	Recovery expected in 2023-2024
Healthcare Digitalization	Facilitates remote consultations, possibly boosting demand	Long-term positive impact

---

How Will the Competitive Landscape Evolve?

Future Developments	Likely Impact on XIPERE
Launch of New Intravitreal Corticosteroids	Potential market share dilution
Emergence of Sustained-release Formulations	May reduce demand for re-treatment cycles
Advancements in Biologics and Gene Therapy	Could shift treatment algorithms, reducing steroid reliance
Combination Therapies Combining Steroids with Biologics	New treatment paradigms and unmet needs

---

What Are the Key Regulatory and Policy Milestones?

Milestone	Expected Date	Impact
FDA approval for additional indications	2023-2024	Expansion of market opportunities
European EMA approval	2024	Geographic expansion, revenue uplift
Reimbursement policy clarity	2023-2025	Accelerated market penetration

---

Key Takeaways

• Market Opportunity: The uveitic macular edema segment offers substantial growth potential, with global patient populations in the millions and a rising prevalence projected to sustain high demand.
• Competitive Edge: As the first-in-class intravitreal hreluvatide suspension, XIPERE benefits from differentiation, assuming safety and efficacy data reinforce its clinical value.
• Revenue Forecasts: Potential revenues could reach USD 300 million by 2027, contingent on successful market penetration and payer acceptance.
• Challenges to Address: Competitive entry, pricing pressures, and regulatory hurdles necessitate strategic planning and proactive stakeholder engagement.
• Strategic Moves: Expanding indications, pursuing global approvals, and forging partnerships can optimize financial trajectory.

---

FAQs

1. What distinguishes XIPERE from existing corticosteroid therapies?
   XIPERE’s novel formulation allows for targeted intravitreal delivery with potentially improved safety and dosing convenience, differentiating it from longer-established implants like Ozurdex.

2. Can XIPERE replace other corticosteroids in uveitis treatment?
   It can complement existing options, particularly where a tailored pharmacokinetic profile and localized therapy are advantageous; however, its adoption depends on clinical data and cost-effectiveness.

3. What are the main barriers to market penetration?
   Entrenched competition, insurer negotiation dynamics, and clinician familiarity with existing implants represent initial hurdles.

4. How might policy changes impact XIPERE’s financial prospects?
   Favorable reimbursement policies and accelerated approval pathways can hasten uptake, while regulatory restrictions could delay growth.

5. What’s the long-term outlook for XIPERE in the ophthalmology market?
   With expanding indications, global approvals, and potential combination therapies, XIPERE’s role could strengthen, securing a stable revenue stream in the growing intraocular steroids market.

---

References

[1] Jabs DA, et al. "Epidemiology of Uveitis." Ophthalmology. 2017;124(7): 920-928.
[2] Grand View Research. "Ophthalmic Corticosteroids Market Size & Share." 2022.